24-07-2026 23:21 via medpagetoday.com

FDA Gets New Avacopan Analysis After Alleging Data Manipulation

(MedPage Today) -- Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA in a bid to keep the embattled drug for severe anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis...
Read more »